Bonds & fixed income
PBEInvescoACTIVE
Invesco Dynamic Biotechnology & Genome ETF
$100.74+1.55% vs prior close
7310152-WK
Price through Oct 27, 2026 · Flows through Oct 26, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 27, 2026. Holdings snapshot retrieved Oct 27, 2026.
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
PBE price
Source: Market tape, daily closes; price return, distributions not reinvested
Table
| Date | PBE close |
|---|---|
| Sep 28, 2026 | $97.29 |
| Sep 29, 2026 | $97.16 |
| Sep 30, 2026 | $97.29 |
| Oct 1, 2026 | $95.10 |
| Oct 2, 2026 | $95.07 |
| Oct 5, 2026 | $97.04 |
| Oct 6, 2026 | $94.70 |
| Oct 7, 2026 | $94.83 |
| Oct 8, 2026 | $94.25 |
| Oct 9, 2026 | $96.90 |
| Oct 12, 2026 | $96.44 |
| Oct 13, 2026 | $94.94 |
| Oct 14, 2026 | $96.72 |
| Oct 15, 2026 | $98.65 |
| Oct 16, 2026 | $96.08 |
| Oct 19, 2026 | $96.71 |
| Oct 20, 2026 | $99.22 |
| Oct 21, 2026 | $99.56 |
| Oct 22, 2026 | $99.38 |
| Oct 23, 2026 | $98.72 |
| Oct 26, 2026 | $99.21 |
| Oct 27, 2026 | $100.74 |
Daily net flows, 1M
Net outflow over the range: −$1M
- Inflow / above zero
- Outflow / below zero
Source: Daily creation and redemption records
Show as table
| Label | Value ($) |
|---|---|
| Sep 28 | $0 |
| Sep 29 | $0 |
| Sep 30 | $0 |
| Oct 1 | $0 |
| Oct 2 | $950K |
| Oct 5 | −$960K |
| Oct 6 | −$960K |
| Oct 7 | $0 |
| Oct 8 | $0 |
| Oct 9 | $0 |
| Oct 12 | −$970K |
| Oct 13 | $0 |
| Oct 14 | $0 |
| Oct 16 | $0 |
| Oct 19 | $0 |
| Oct 20 | $0 |
| Oct 21 | $0 |
| Oct 22 | $0 |
| Oct 23 | $980K |
| Oct 26 | $0 |
The desk’s read
Money is leaving — −$960K in net outflows over the past month, about 0.2% of the fund's asset base, while the price has returned +22.6% so far this year. At 0.58% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
$432Massets under management
0.58%expense ratio · $58 per $10,000 a year
−$960Knet flow, trailing month
13Kavg daily volume, 30 days
31holdings · US-domiciled
2005listed June 23, 2005 · beta 0.64
The book at a glance
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
Holdings
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | ILMNILLUMINA | 5.98% | $279.47 | +3.1% | ||
| 2 | NTRANATERA | 5.97% | $410.82 | +1.5% | ||
| 3 | BIIBBIOGEN | 5.67% | $252.73 | +0.2% | ||
| 4 | GILDGILEAD SCIENCES | 5.30% | $159.08 | +0.2% | ||
| 5 | RPRXROYALTY PHARMA | 5.18% | $65.28 | +0.8% | ||
| 6 | AMGNAMGEN | 4.99% | $447.95 | +0.7% | ||
| 7 | REGNREGENERON PHARMACEUTICALS | 4.81% | $816.10 | +1.0% | ||
| 8 | VRTXVERTEX PHARMACEUTICALS | 4.65% | $521.03 | +0.7% | ||
| 9 | MRNAMODERNA | 3.39% | $207.97 | +4.6% | ||
| 10 | HALOHALOZYME THERAPEUTICS | 3.17% | $128.50 | +0.4% | ||
| 11 | EXELEXELIXIS | 3.11% | $65.35 | +0.4% | ||
| 12 | QGENQIAGEN NV | 3.13% | $50.17 | -0.4% | ||
| 13 | VCYTVERACYTE | 2.96% | $50.28 | +4.3% | ||
| 14 | UTHRUNITED THERAPEUTICS | 3.10% | $591.20 | -0.3% | ||
| 15 | NVAXNOVAVAX | 2.70% | $10.02 | +6.6% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 31Sector weights
- Healthcare100%
- Health Technology91.43%
- Health Services8.5%
- Other0.1%
- Mutual fund0.08%
Source: Portfolio composition, latest disclosure
Show as table
| Item | Value (%) |
|---|---|
| Healthcare | 100% |
| Health Technology | 91.43% |
| Health Services | 8.5% |
| Other | 0.1% |
| Mutual fund | 0.08% |
Country weights
- United States100%
- Ireland3.05%
- Netherlands2.73%
- Canada2.43%
Source: Portfolio composition, latest disclosure
Show as table
| Item | Value (%) |
|---|---|
| United States | 100% |
| Ireland | 3.05% |
| Netherlands | 2.73% |
| Canada | 2.43% |
Performance
| 1 week | +1.2% |
| 1 month | +3.6% |
| 3 months | +12.1% |
| 6 months | +26.2% |
| YTD | +22.6% |
| 1 year | +36.5% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
Net flows
| 1 week | +$980K |
| 1 month | −$960K |
| 3 months | +$111M |
| YTD | +$113M |
| 1 year | +$113M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
Monthly net flows
- Inflow / above zero
- Outflow / below zero
Source: Daily creation/redemption records, trailing twelve months
Show as table
| Label | Value ($) |
|---|---|
| Aug | −$17.5M |
| Sep | −$3.5M |
| Oct | $0 |
| Feb | $3.2M |
| Mar | −$5.4M |
| Apr | $30K |
| May | −$1.6M |
| Jun | $1.6M |
| Jul | $4.6M |
| Aug | $161.2M |
| Sep | −$50.1M |
| Oct | −$960K |
The risk read
25%realized volatility, 30 days (annualized)
20%realized volatility, 1 year
-11.8%deepest fall from a peak, 1 year
at peaklatest close versus that peak
The top holding is 6.0% of the book; the top ten carry 49%. Spread across 32+ names, it behaves like roughly 26 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
Options tape
—calls · latest snapshot
—puts · latest snapshot
—put/call ratio
5Kshares traded
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $52M | $53M |
| AMGN AMGEN | $64M | $2M |
| NTRA NATERA | $2M | $2M |
| GILD GILEAD SCIENCES | $2M | $738,877 |
| REGN REGENERON PHARMACEUTICALS | $752,963 | $1M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
The case against PBE
Due diligence cuts both ways. These funds sit on the same shelf and beat PBE on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW SPDR Portfolio Developed World ex-US ETF | 0.03% | $40.7B | +$609M | -55bp on fee · 94× the assets · +$609M in over the month | Head-to-head |
| BBUS JPMorgan BetaBuilders U.S. Equity ETF | 0.02% | $9.6B | +$187M | -56bp on fee · 22× the assets · +$187M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -55bp on fee · 42× the assets · +$199M in over the month | Head-to-head |
| SPYG State Street SPDR Portfolio S&P 500 Growth ETF | 0.04% | $57.9B | +$717M | -54bp on fee · 134× the assets · +$717M in over the month | Head-to-head |
| SPTM State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF | 0.03% | $14.2B | +$235M | -55bp on fee · 33× the assets · +$235M in over the month | Head-to-head |